MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Evotec AG

Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology
From Evotec AG
Via AccessWire
Tickers EVO EVOTF
Evotec and Sernova Announce Exclusive Strategic Partnership for iPSC-based Beta Cell Replacement Therapy to Advance a 'Functional Cure' for Diabetes
From Evotec AG
Via AccessWire
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership
From Evotec AG
Via AccessWire
Tickers EVO
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation
From Evotec AG
Via AccessWire
Tickers EVO
Evotec SE to Announce Results for the First Quarter 2022 on 11 May 2022
From Evotec AG
Via AccessWire
Tickers EVO
Evotec SE Fiscal Year 2021 Results: 'Setting the Pace' on the Data-Driven R&D Autobahn to Cures
From Evotec AG
Via AccessWire
Tickers EVO EVOTF
Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb
From Evotec AG
Via AccessWire
Tickers EVO EVOTF
Evotec SE to Announce Results for Fiscal Year 2021 on 12 April 2022
From Evotec AG
Via AccessWire
Tickers EVO
Evotec Receives € 3 m Milestone Payment for Bayer Starting Phase II Clinical Development of DNP Programme
From Evotec AG
Via AccessWire
Tickers EVO
Evotec Presents Strategic Roadmap Towards Precision Medicine and Confirms Goals of Action Plan 2025 at Capital Markets Day
From Evotec AG
Via AccessWire
Topics Artificial Intelligence
Tickers EVO
Evotec Expands Molecular Patient Database with Unique Nephrotic Syndrome Cohort from the University of Bristol
From Evotec AG
Via AccessWire
Tickers EVO
Bayer Discontinues Clinical Development Candidate Eliapixant (BAY1817080), Evotec Regains the Rights to all P2X3 Assets
From Evotec AG
Via AccessWire
Tickers EVO
Evotec Enters iPSC-based Drug Discovery Partnership with Boehringer Ingelheim in Ophthalmology
From Evotec AG
Via AccessWire
Tickers EVO
Evotec and Lilly Enter into Drug Discovery Collaboration in Metabolic Diseases
From Evotec AG
Via AccessWire
Tickers EVO
Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach
From Evotec AG
Via AccessWire
Evotec Receives € 7.5 m Grant for Development of COVID-19 Therapeutic
From Evotec AG
Via AccessWire
Tickers EVO EVOTF
Evotec Receives US$ 18 M Grant for Women's Health
From Evotec AG
Via AccessWire
Evotec and EQRx Announce Integrated Drug Discovery and Development Partnership
From Evotec AG
Via AccessWire
Tickers EVO
Evotec SE Reports Results for the First Nine Months 2021 and Provides Corporate Update
From Evotec AG
Via AccessWire
Topics Initial Public Offering
Evotec Reaches Programme Designations in Neuroscience Collaboration with Bristol Myers Squibb
From Evotec AG
Via AccessWire
Tickers EVO
Evotec SE Announces Closing of Public Offering
From Evotec AG
Via AccessWire
Tickers EVO
Evotec SE Announces Placement of Its Public Offering of American Depositary Shares
From Evotec AG
Via AccessWire
Topics Regulatory Compliance
Evotec SE To Announce Results for the First Nine Months 2021 On 11 November 2021
From Evotec AG
Via AccessWire
Topics Regulatory Compliance
Evotec SE: Announces Launch of Public Offering of American Depositary Shares
From Evotec AG
Via AccessWire
Topics Regulatory Compliance
Evotec Provides Preliminary Nine Month Financial Results
From Evotec AG
Via AccessWire
Evotec SE files Registration Statement for Proposed Offering of American Depositary Shares
From Evotec AG
Via AccessWire
Topics Regulatory Compliance
Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include Novel Cell Type
From Evotec AG
Via AccessWire
Evotec Announces Bristol Myers Squibb Opt-in of EVT8683 as the First Programme from iPSC-based Neurodegeneration Collaboration
From Evotec AG
Via AccessWire
Just - Evotec Biologics Opens J.POD 1 US in Redmond, Washington
From Evotec AG
Via AccessWire
Evotec SE Reports First Half-Year 2021 Results and Corporate Updates
From Evotec AG
Via AccessWire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story